presented by j. richard creekmore us technology manager astrazeneca pharmaceuticals process...

4
Presented By J. Richard Creekmore US Technology Manager AstraZeneca Pharmaceuticals Process Robustness: Development to Life Cycle Management

Upload: alex-macdonald

Post on 27-Mar-2015

224 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Presented By J. Richard Creekmore US Technology Manager AstraZeneca Pharmaceuticals Process Robustness: Development to Life Cycle Management

Presented ByJ. Richard Creekmore

US Technology ManagerAstraZeneca Pharmaceuticals

Process Robustness: Development to Life Cycle

Management

Page 2: Presented By J. Richard Creekmore US Technology Manager AstraZeneca Pharmaceuticals Process Robustness: Development to Life Cycle Management

Tolerance Limits

• Understanding of tolerances comes from experimentation (DOE) and experience.

• Best to have ranges for as many variables as possible, but not practical.

• Decide which ones are more important (QRA)• Some cannot be determined because no method

can determine the difference. Only downstream processing and testing might work, e.g. blend uniformity of a non-flowing mixture.

Page 3: Presented By J. Richard Creekmore US Technology Manager AstraZeneca Pharmaceuticals Process Robustness: Development to Life Cycle Management

Operating Ranges

Δ Zone

Proven acceptable range or design space may not fill the operating range completely

Page 4: Presented By J. Richard Creekmore US Technology Manager AstraZeneca Pharmaceuticals Process Robustness: Development to Life Cycle Management

Process Robustness: From Development to Life Cycle ManagementOctober 10, 2013 11:15am - 12:15pmRichard Creekmore, US Technology Manager, AstraZeneca PharmaceuticalsTrack: Manufacturing & OperationsLevel: Beginner

To register for the INTERPHEX Puerto Rico Educational Program, please visit:

www.interphexpuertorico.com/en/Register-Now/

October 10-11, 2013 | Puerto Rico Convention Center | San Juan, Puerto Rico